Form 4: Evolent Health Director Richard Jelinek Reports Acquisition of Restricted Stock Units

Richard Jelinek, a director at Evolent Health, Inc., reported the acquisition of restricted stock units (RSUs) under the company's 2015 Omnibus Incentive Compensation Plan.

Summary

• On June 6, 2024, Richard M Jelinek, a director of Evolent Health, Inc., acquired 7,709 shares of Class A Common Stock.
• These shares were obtained through restricted stock units (RSUs) granted under the company's 2015 Omnibus Incentive Compensation Plan.
• The RSUs vest on the earlier of June 6, 2025, or the date of the company's 2025 annual meeting, contingent upon Jelinek's continued service.
• Following the transaction, Jelinek beneficially owns 14,458 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (granting of RSUs) and doesn't contain any alarming or negative information. It suggests continued alignment of the director's interests with the company's performance.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's long-term success.
• The vesting schedule, contingent on continued service, encourages the director's ongoing commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs in 2025 suggests an expectation of continued service and contribution from the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates that a director has received additional equity compensation, which is a common practice in publicly traded companies.

Stakeholder Impact

• The grant of RSUs aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates